7370 Stock Overview
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NexImmune, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.30 |
| 52 Week High | US$16.88 |
| 52 Week Low | US$3.30 |
| Beta | 1.75 |
| 1 Month Change | 0% |
| 3 Month Change | -31.25% |
| 1 Year Change | -60.48% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7370 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 0.5% |
| 1Y | -60.5% | -22.8% | 1.3% |
Return vs Industry: 7370 underperformed the German Biotechs industry which returned -25.9% over the past year.
Return vs Market: 7370 underperformed the German Market which returned -2% over the past year.
Price Volatility
| 7370 volatility | |
|---|---|
| 7370 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7370's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 7370's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 50 | Kristi Jones | www.neximmune.com |
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage.
NexImmune, Inc. Fundamentals Summary
| 7370 fundamental statistics | |
|---|---|
| Market cap | €9.89m |
| Earnings (TTM) | -€40.39m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs 7370 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7370 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$43.88m |
| Earnings | -US$43.88m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -41.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 7370 perform over the long term?
See historical performance and comparison